Response to 'Vitamin D Status in Scarring and Nonscarring Alopecia'

The document is a response to a study on the role of Vitamin D in scarring and nonscarring alopecia. It supports the recommendation of prescribing Vitamin D to patients with alopecia, but challenges the assertion that cholecalciferol is the optimal treatment. Instead, it recommends the application of topical calcipotriol 0.005% to alopecic lesions twice daily for 12 weeks. This recommendation is based on several studies that showed promising results with Vitamin D supplementation. For instance, a study with 40 women suffering from telogen effluvium showed significant hair regrowth in 82.5% of subjects after only 6 doses of high-dose (200,000 IU) oral vitamin D supplements. Another study with 60 patients with alopecia areata (AA) showed that calcipotriol was significantly more effective than placebo in improving the Severity of Alopecia Tool score. However, the document emphasizes the need for double-blinded, randomized clinical trials to ascertain the clinical benefits of Vitamin D supplementation in scarring and nonscarring alopecia.